Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy.

Division of Breast Surgery, European Institute of Oncology, Via Ripamonti, 435, 20141, Milan, Italy.
Annals of Surgical Oncology (Impact Factor: 3.94). 12/2005; 12(11):895-9. DOI: 10.1245/ASO.2005.10.018
Source: PubMed

ABSTRACT Sentinel lymph node biopsy (SLNB) is a safe and accurate axillary staging procedure for patients with primary operable breast cancer. An increasing proportion of these patients undergo breast-conserving surgery, and 5% to 15% will develop local relapses that necessitate reoperation. Although a previous SLNB is often considered a contraindication for a subsequent SLNB, few data support this concern.
Between January 2000 and June 2004, 79 patients who were previously treated at our institution with breast-conserving surgery and who had a negative SLNB for early breast cancer developed, during follow-up, local recurrence that was amenable to reoperation. Eighteen of these patients were offered a second SLNB because of a clinically negative axillary status an average of 26.1 months after the primary event.
In all 18 patients (7 with ductal carcinoma-in-situ and 11 with invasive recurrences), preoperative lymphoscintigraphy showed an axillary sentinel lymph node, with a preoperative identification rate of 100%, and 1 or more SLNs (an average of 1.3 per patient) were surgically removed. Sentinel lymph node metastases were detected in two patients with invasive recurrence, and a complete axillary dissection followed. At a median follow up of 12.7 months, no axillary recurrences have occurred in patients who did not undergo axillary dissection.
Second SLNB after previous SLNB is technically feasible and likely effective in selected breast cancer patients. A larger population and longer follow-up are necessary to confirm these preliminary data.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite new development and knowledge of molecular medicine, axillary node status remains the most potent prognostic determinant in patients with early breast cancer. Since only a small percentage of patients with operable breast cancer will be found to have involved axillary nodes, conventional axillary lymph node dissection (ALND), which is associated with unjustifiably high morbidity, is’ unnecessary’ for the majority of the patients. Today, sentinel lymph node biopsy (SLNB) is considered a safe, accurate and sensitive, minimally invasive technique to stage the axilla of women with early breast cancer and clinically uninvolved axillary lymph nodes. It is a targeted approach with low false negative rates, no obvious negative impact on locoregional control and it is associated with significantly less morbidity than ALND. In view of the recently published randomized control trial assessing the long term outcomes and the safety of this technique, this review paper aims to summarize the story so far, discuss the indications, contraindications and debatable issues and provide up to date knowledge about the SLNB
    Hellēnikē cheirourgikē. Acta chirurgica Hellenica 02/2012; 84(1). DOI:10.1007/s13126-012-0004-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: In patients with recurrent or second primary ipsilateral breast cancer, axillary staging is the key factor in locoregional control and a strong prognostic characteristic. The efficient evaluation of lymphatic drainage of re-sentinel lymph node biopsies (re-SLNBs) has remained a challenge in the management of ipsilateral primary or recurrent breast cancer patients who are clinically lymph node negative. This study explores whether a SLNB for patients with primary or recurrent breast cancer is possible after previous axillary surgery. It evaluates potential reasons for mapping failure that might be associated with patients in this group.
    World Journal of Surgical Oncology 07/2014; 12(1):205. DOI:10.1186/1477-7819-12-205 · 1.20 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is a prevalent disease affecting all areas of patients' lives. Therefore, family physicians must thoroughly understand this pathology in order to optimize the health care services and make the best use of available resources, for these patients. A series of 5 articles on breast cancer is presented below. It is based on a review of the scientific literature over the last 10 years. This fourth article deals with the treatment of the disease, the role of the primary care physician, and management of major complications. This summary report aims to provide a current and practical review about this problem, providing answers to family doctors and helping them to support their patients and care for them throughout their illness.